Physician profile
Robert Kincaid
NPI 1386650406
$509.65
in general payments reported to CMS, 2019-2025
13 companies · $25.76 in 2025
The $25.76 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2022: $12.00 · 2023: $30.18 · 2024: $32.56 · 2025: $25.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $88.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $88.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $98.97 | 2019 | |
| Novo Nordisk INC | $91.55 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $64.59 | 2019 | |
| Abbott Laboratories | $41.00 | 2022-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.87 | 2019 | |
| Pfizer INC. | $31.84 | 2019 | |
| Glaxosmithkline, LLC. | $29.25 | 2019 | |
| Amgen INC. | $28.05 | 2019 | |
| Dexcom, INC. | $25.76 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.52 | 2019 | |
| Sanofi Pasteur INC. | $13.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.99 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kincaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.